Comparative studies on retroviral proteases: Substrate specificity

Viruses

Volumn 2, Issue 1, 2010, Pages 147-165

  Tözsér, József ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

HIV protease; Retroviral proteases; Substrate specificity

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE 1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE 2; PROTEINASE; UNCLASSIFIED DRUG; VIRUS ENZYME;

BINDING SITE; COMPARATIVE STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; ENZYME SPECIFICITY; FRAMESHIFT MUTATION; HYDROLYSIS; HYDROPHOBICITY; IONIC STRENGTH; IONIZATION; LENTIVIRINAE; NONHUMAN; PH; PHYLOGENETIC TREE; PHYLOGENY; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN SYNTHESIS; RETROVIRUS; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; VIRION; VIRUS MORPHOLOGY; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79952089811     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2010147     Document Type: Review

References (80)

1. Weiss, R.A. The discovery of endogenous retroviruses. Retrovirology 2006, 3, 67.
2. Oroszlan, S.; Luftig, R.B. Retroviral proteinases. Curr. Top. Microbiol. Immunol. 1990, 157, 153-185.
3. Henderson, L.E.; Benveniste, R.E.; Sowder, R.; Copeland, T.D.; Schultz, A.M.; Oroszlan, S. Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne). J. Virol. 1988, 62, 2587-2595.
4. Pettit, S.C.; Simsic, J.; Loeb, D.D.; Everitt, L.; Hutchison, C.A. 3rd.; Swanstrom, R. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. J. Biol. Chem. 1991, 266, 14539-14547.
5. Griffiths, J.T.; Phylip, L.H.; Konvalinka, J.; Strop, P.; Gustchina, A.; Wlodawer, A.; Davenport, R.J.; Briggs, R.; Dunn, B.M.; Kay, J. Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites. Biochemistry 1992, 31, 5193-51200.
6. Tözsér, J.; Bagossi, P.; Weber, I.T.; Louis, J.M.; Copeland, T.D.; Oroszlan, S. Studies on the symmetry and sequence context dependence of the HIV-1 proteinase specificity. J. Biol. Chem. 1997, 272, 16807-16814.
7. Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27, 157-162.
8. Oroszlan S.; Henderson, L.E.; Stephenson, J.R.; Copeland, T.D.; Long, C.W.; Ihle, J.N.; Gilden, R.V. Amino- and carboxyl-terminal amino acid sequences of proteins coded by gag gene of murine leukemia virus. Proc. Natl. Acad. Sci. USA 1978, 75, 1404-1408.
9. Weber, I.T.; Agniswamy, J. HIV-1 Protease: Structural Perspectives on Drug Resistance. Viruses 2009, 1, 1110-1136.
10. Dunn, B.M.; Goodenow, M.M.; Gustchina, A.; Wlodawer, A. Retroviral proteases. Genome Biol. 2002, 3, reviews3006.1-3006.7.
11. Tomasselli, A.G.; Heinrikson, R.L. Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates. Methods Enzymol. 1994, 241, 279-301.
12. Dunn, B.M.; Gustchina, A.; Wlodawer, A.; Kay, J. Subsite preferences of retroviral proteinases. Methods Enzymol. 1994, 241, 254-278.
13. Louis, J.M.; Weber, I.T.; Tözsér, J.; Clore, G.M.; Gronenborn, A.M. HIV-1 protease: maturation, enzyme specificity, and drug resistance. Adv. Pharmacol. 2000, 49, 111-146.
14. Tözsér, J.; Oroszlan, S. Proteolytic events of HIV-1 replication as targets for therapeutic intervention. Curr. Pharm. Des. 2003, 9, 1803-1815.
15. Pettit, S.C.; Moody, M.D.; Wehbie, R.S.; Kaplan, A.H.; Nantermet, P.V.; Klein, C.A.; Swanstrom, R. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 1994, 68, 8017-8027.
16. Boross, P.; Bagossi, P.; Copeland, T.D.; Oroszlan, S.; Louis, J.M.; Tözsér, J. Effect of substrate residues on the P2' preference of retroviral proteinases. Eur. J. Biochem. 1999, 264, 921-929.
17. Prabu-Jeyabalan, M.; Nalivaika, E.; Schiffer, C.A. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 2002, 10, 369-381.
18. Tie, Y.; Boross, P.I.; Wang, Y.F.; Gaddis, L.; Liu, F.; Chen, X.; Tözsér, J.; Harrison, R.W.; Weber, I.T. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J. 2005, 272, 5265-5277.
19. Tözsér, J.; Weber, I.T.; Gustchina, A.; Bláha, I.; Copeland, T.D.; Louis, J.M.; Oroszlan, S. Kinetic and modeling studies of S3-S3' subsites of HIV proteinases. Biochemistry 1992, 31, 4793-4800.
20. Shafer, R.W.; Schapiro, J.M. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 2008, 10, 67-84.
21. Weber, I.T.; Zhang, Y.; Tözsér, J. HIV-1 Protease and AIDS Therapy. In Proteases in Biology and Diseases, Volume 8, Lendeckel, U.; Hooper, M.N., Eds.; Springer: Berlin, Germany, 2009; pp. 25-45.
22. Gulnik, S.V.; Suvorov, L.I.; Liu, B.; Yu, B.; Anderson, B.; Mitsuya, H.; Erickson, J.W. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995, 34, 9282-9287.
23. King, N.M.; Prabu-Jeyabalan, M.; Nalivaika, E.A.; Schiffer, C.A. Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem. Biol. 2004, 11, 1333-1338.
24. Bock, P.J.; Markovitz, D.M. Infection with HIV-2. AIDS 2001, 15 (Suppl. 5), S35-45.
25. Tözsér, J.; Bláha, I.; Copeland, T.D.; Wondrak, E.M.; Oroszlan, S. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett. 1991, 281, 77-80.
26. Wu, J.C.; Carr, S.F.; Jarnagin, K.; Kirsher, S.; Barnett, J.; Chow, J.; Chan, H.W.; Chen, M.S.; Medzihradszky, D.; Yamashiro, D.; et al. Synthetic HIV-2 protease cleaves the GAG precursor of HIV-1 with the same specificity as HIV-1 protease. Arch. Biochem. Biophys. 1990, 277, 306-311.
27. Pichuantes, S.; Babé, L.M.; Barr, P.J.; DeCamp, D.L.; Craik, C.S. Recombinant HIV2 protease processes HIV1 Pr53gag and analogous junction peptides in vitro. J. Biol. Chem. 1990, 265, 13890-13898.
28. Tomasselli, A.G.; Hui, J.O.; Sawyer, T.K.; Staples, D.J.; Bannow, C.; Reardon, I.M.; Howe, W.J.; DeCamp, D.L.; Craik, C.S.; Heinrikson, R.L. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J. Biol. Chem. 1990, 265, 14675-14683.
29. Poorman, R.A.; Tomasselli, A.G.; Heinrikson, R.L.; Kézdy, F.J. A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate database. J. Biol. Chem. 1991, 266, 14554-14561.
30. Tözsér, J.; Gustchina, A.; Weber, I.T.; Blaha, I.; Wondrak, E.M.; Oroszlan S. Studies on the role of the S4 substrate binding site of HIV proteinases. FEBS Lett. 1991, 279, 356-360.
31. Bagossi, P.; Cheng, Y.S.; Oroszlan, S.; Tözsér, J. Comparison of the specificity of homo- and heterodimeric linked HIV-1 and HIV-2 proteinase dimers. Protein Eng. 1998, 11, 439-445.
32. Brower, E.T.; Bacha, U.M.; Kawasaki, Y.; Freire, E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des. 2008, 71, 298-305.
33. Menéndez-Arias, L.; Tözsér, J. HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends Pharmacol Sci. 2008, 29, 42-49.
34. Tomasselli, A.G.; Bannow, C.A.; Deibel, M.R., Jr.; Hui, J.O.; Zurcher-Neely, H.A.; Reardon, I.M.; Smith, C.W.; Heinrikson, R.L. Chemical synthesis of a biotinylated derivative of the simian immunodeficiency virus protease. Purification by avidin affinity chromatography and autocatalytic activation. J. Biol. Chem. 1992, 267, 10232-10237.
35. Rushlow, K.; Peng, X.X.; Montelaro, R.C.; Shih, D.S. Expression of the protease gene of equine infectious anemia virus in Escherichia coli: formation of the mature processed enzyme and specific cleavage of the gag precursor. Virology 1992, 188, 396-401.
36. Luukkonen, B.G.; Tan, W.; Fenyö, E.M.; Schwartz, S. Analysis of cross reactivity of retrovirus proteases using a vaccinia virus-T7 RNA polymerase-based expression system. J. Gen. Virol. 1995, 76, 2169-2180.
37. Powell, D.J.; Bur, D.; Wlodawer, A.; Gustchina, A.; Payne, S.L.; Dunn, B.M.; Kay, J. Expression, characterisation and mutagenesis of the aspartic proteinase from equine infectious anaemia virus. Eur. J. Biochem. 1996, 241, 664-674.
38. Weber, I.T.; Tözsér, J.; Wu, J.; Friedman, D.; Oroszlan S. Molecular model of equine infectious anemia virus proteinase and kinetic measurements for peptide substrates with single amino acid substitutions. Biochemistry 1993, 32, 3354-3362.
39. Tözsér, J.; Friedman, D.; Weber, I.T.; Bláha, I.; Oroszlan, S. Studies on the substrate specificity of the proteinase of equine infectious anemia virus using oligopeptide substrates. Biochemistry 1993, 32, 3347-3353.
40. Wlodawer, A.; Gustchina, A.; Reshetnikova, L.; Lubkowski, J.; Zdanov, A.; Hui, K.Y.; Angleton, E.L.; Farmerie, W.G.; Goodenow, M.M.; Bhatt, D. et al. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus. Nat. Struct. Biol. 1995, 2, 480-488.
41. Lin, Y.C.; Beck, Z.; Lee, T.; Le, V.D.; Morris, G.M.; Olson, A.J.; Wong, C.H.; Elder, J.H. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease. J. Virol. 2000, 74, 4710-4720.
42. Beck, Z.Q.; Lin, Y.C.; Elder, J.H. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases. J. Virol. 2001, 75, 9458-9469.
43. Lin, Y.C.; Beck, Z.; Morris, G.M.; Olson, A.J.; Elder, J.H. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases. J. Virol. 2003, 77, 6589-6600.
44. Schnölzer, M.; Rackwitz, H.R.; Gustchina, A.; Laco, G.S.; Wlodawer, A.; Elder, J.H.; Kent, S.B. Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis. Virology 1996, 224, 268-275.
45. Bagossi, P.; Sperka, T.; Fehér, A.; Kádas, J.; Zahuczky, G.; Miklóssy, G.; Boross, P.; Tözsér, J. Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites. J. Virol. 2005, 79, 4213-4218.
46. Miller, M.; Jaskólski, M.; Rao, J.K.; Leis, J.; Wlodawer, A. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature 1989, 337, 576-579.
47. Konvalinka, J.; Horejsí, M.; Andreánsky, M.; Novek, P.; Pichová, I.; Bláha, I.; Fábry, M.; Sedlácek, J.; Foundling, S.; Strop, P.; An engineered retroviral proteinase from myeloblastosis associated virus acquires pH dependence and substrate specificity of the HIV-1 proteinase. EMBO J. 1992, 11, 1141-1144.
48. Grinde, B.; Cameron, C.E.; Leis, J.; Weber, I.T.; Wlodawer, A.; Burstein, H.; Bizub, D.; Skalka, A.M. Mutations that alter the activity of the Rous sarcoma virus protease. J. Biol. Chem. 1992, 267, 9481-9490.
49. Grinde, B.; Cameron, C.E.; Leis, J.; Weber, I.T.; Wlodawer, A.; Burstein, H.; Skalka AM. Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. J. Biol. Chem. 1992, 267, 9491-9498.
50. Cameron, C.E.; Grinde, B.; Jacques, P.; Jentoft, J.; Leis, J.; Wlodawer, A.; Weber, I.T. Comparison of the substrate-binding pockets of the Rous sarcoma virus and human immunodeficiency virus type 1 proteases. J. Biol. Chem. 1993, 268, 11711-11720.
51. Cameron, C.E.; Ridky, T.W.; Shulenin, S.; Leis, J.; Weber, I.T.; Copeland, T.; Wlodawer, A.; Burstein, H.; Bizub-Bender, D.; Skalka, A.M. Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases. J. Biol. Chem. 1994, 269, 11170-11177.
52. Strop, P.; Konvalinka, J.; Stys, D.; Pavlickova, L.; Blaha, I.; Velek, J.; Travnicek, M.; Kostka, V.; Sedlacek, J. Specificity studies on retroviral proteinase from myeloblastosis-associated virus. Biochemistry 1991, 30, 3437-3443.
53. Tözsér, J.; Bagossi, P.; Weber, I.T; Copeland, T.D.; Oroszlan, S. Comparative studies on the substrate specificity of avian myeloblastosis virus proteinase and lentiviral proteinases. J. Biol. Chem. 1996, 271, 6781-6788.
54. Menéndez-Arias, L.; Young, M.; Oroszlan, S. Purification and characterization of the mouse mammary tumor virus protease expressed in Escherichia coli. J. Biol. Chem. 1992, 267, 24134-24139.
55. Hrusková-Heidingsfeldová, O.; Andreansky, M.; Fábry, M.; Bláha, I.; Strop, P.; Hunter, E. Cloning, bacterial expression, and characterization of the Mason-Pfizer monkey virus proteinase. J. Biol. Chem. 1995, 270, 15053-15058.
56. Rumlová, M.; Ruml, T.; Pohl, J.; Pichová, I. Specific in vitro cleavage of Mason-Pfizer monkey virus capsid protein: evidence for a potential role of retroviral protease in early stages of infection. Virology 2003, 310, 310-318.
57. Tözsér, J.; Shulenin, S.; Kádas, J.; Boross, P.; Bagossi, P.; Copeland, T.D.; Nair, B.C.; Sarngadharan, M.G.; Oroszlan, S. Human immunodeficiency virus type 1 capsid protein is a substrate of the retroviral proteinase while integrase is resistant toward proteolysis. Virology 2003, 310, 16-23.
58. Yoshinaka, Y.; Katoh, I.; Copeland, T.D.; Oroszlan, S. Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon. Proc. Natl. Acad. Sci. USA 1985, 82, 1618-1622.
59. nd Ed.; Barrett, A.J., Rawlings, N.D., Woessner, J.F., Eds.; Elsevier: London, UK, 2004; pp. 176-178.
60. Menendez-Arias, L.; Gotte, D.; Oroszlan, S. Moloney murine leukemia virus protease: bacterial expression and characterization of the purified enzyme. Virology 1993, 196, 557-563.
61. Fehér, A.; Boross, P.; Sperka, T.; Miklóssy, G.; Kádas, J.; Bagossi, P.; Oroszlan, S.; Weber, I.T.; Tözsér, J. Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease. J. Gen. Virol. 2006, 87, 1321-1330.
62. Menéndez-Arias, L.; Weber, I.T.; Soss, J.; Harrison, R.W.; Gotte, D.; Oroszlan, S. Kinetic and modeling studies of subsites S4-S3' of Moloney murine leukemia virus protease. J. Biol. Chem. 1994, 269, 16795-16801.
63. Cannon, K.; Qin, L.; Schumann, G.; Boeke, J.D. Moloney murine leukemia virus protease expressed in bacteria is enzymatically active. Arch. Virol. 1998, 143, 381-388.
64. Johnson, J.M.; Harrod, R.; Franchini, G. Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus Type-1 (HTLV-1). Int. J. Exp. Pathol. 2001, 82, 135-147.
65. Hrusková-Heidingsfeldová, O.; Bláha, I.; Urban, J.; Strop, P.; Pichová, I. Substrates and inhibitors of human T-cell leukemia virus type 1 (HTLV-1) proteinase. Leukemia 1997, 11 Supp l3, 45-46.
66. Sperka, T.; Miklóssy, G.; Tie, Y.; Bagossi, P.; Zahuczky, G.; Boross, P.; Matúz, K.; Harrison, R.W.; Weber, I.T.; Tözsér, J. Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases. J. Gen. Virol. 2007, 88, 2052-2063.
67. Kádas, J.; Weber, I.T.; Bagossi, P.; Miklóssy, G.; Boross, P.; Oroszlan, S.; Tözsér, J. Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease. J. Biol. Chem. 2004, 279, 27148-27157.
68. Zahuczky, G.; Boross, P.; Bagossi, P.; Emri, G.; Copeland, T.D.; Oroszlan, S.; Louis, J.M.; Tözsér, J. Cloning of the bovine leukemia virus proteinase in Escherichia coli and comparison of its specificity to that of human T-cell leukemia virus proteinase. Biochim. Biophys. Acta. 2000, 1478, 1-8.
69. Flügel, R.M.; Pfrepper, K.I. Proteolytic processing of foamy virus Gag and Pol proteins. Curr. Top. Microbiol. Immunol. 2003, 277, 63-88.
70. Khan, A.S. Simian foamy virus infection in humans: prevalence and management. Expert Rev. Anti Infect. Ther. 2009, 7, 569-580.
71. Pfrepper, K.I.; Flügel, R.M. Molecular characterization of proteolytic processing of the Gag proteins of human spumaretrovirus. Methods Mol. Biol. 2005, 304, 435-444.
72. Roy, J.; Linial, M.L. Role of the foamy virus Pol cleavage site in viral replication. J. Virol. 2007, 81, 4956-4962.
73. Konvalinka, J.; Löchelt, M.; Zentgraf, H.; Flügel, R.M.; Kräusslich, H.G. Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein. J. Virol. 1995, 69, 7264-7268.
74. Fenyöfalvi, G.; Bagossi, P.; Copeland, T.D.; Oroszlan, S.; Boross, P.; Tözsér, J. Expression and characterization of human foamy virus proteinase. FEBS Lett. 1999, 462, 397-401.
75. Eizert, H.; Bander, P.; Bagossi, P.; Sperka, T.; Miklóssy, G.; Boross, P.; Weber, I.T.; Tözsér, J. Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site. J. Virol. 2008, 82, 10111-10117.
76. Fodor, S.K.; Vogt, V.M. Characterization of the protease of a fish retrovirus, walleye dermal sarcoma virus. J. Virol. 2002, 76, 4341-4349.
77. Holzschu, D.L.; Martineau, D.; Fodor, S.K.; Vogt, V.M.; Bowser, P.R.; Casey, J.W. Nucleotide sequence and protein analysis of a complex piscine retrovirus, walleye dermal sarcoma virus. J. Virol. 1995, 69, 5320-5331.
78. Konvalinka, J.; Heuser, A.M.; Hruskova-Heidingsfeldova, O.; Vogt, V.M.; Sedlacek, J.; Strop, P.; Kräusslich, H.G. Proteolytic processing of particle-associated retroviral polyproteins by homologous and heterologous viral proteinases. Eur. J. Biochem. 1995, 228, 191-188.
79. Snásel, J.; Shoeman, R.; Horejsí, M.; Hrusková-Heidingsfeldová, O.; Sedlácek, J.; Ruml, T.; Pichová, I. Cleavage of vimentin by different retroviral proteases Arch. Biochem. Biophys. 2000, 377, 241-245.
80. Alvarez, E.; Castelló, A.; Menéndez-Arias, L.; Carrasco, L. HIV protease cleaves poly(A)-binding protein. Biochem. J. 2006, 396, 219-226.